Skip to main content
Log in

Risk targeting has no impact on CE of lung cancer screening

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. 2016 US dollars

References

  1. Kumar V, et al. Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis. Annals of Internal Medicine : 2 Jan 2018. Available from: URL: http://dx.doi.org/10.7326/M17-1401.

  2. Green AK, et al. Model-Based Eligibility for Lung Cancer Screening: Where Theory Meets Practice. Annals of Internal Medicine : 2 Jan 2018. Available from: URL: http://dx.doi.org/10.7326/M17-3316.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Risk targeting has no impact on CE of lung cancer screening. PharmacoEcon Outcomes News 794, 27 (2018). https://doi.org/10.1007/s40274-018-4625-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4625-8

Navigation